Bristol-Myers Squibb Co at Barclays Global Healthcare Conference Transcript
Okay, welcome to a special afternoon lunch session where -- I'm Geoff Meacham. I'm the senior biopharma analyst here, and Olivia from my team is on stage with me. We're excited to have Bristol. And up on stage with me is Charlie Bancroft, CFO; and John Elicker from the IR team.
Questions & Answers
So maybe let's start with, Charlie, just kind of what your perspective of -- actually, the topic du jour is the Celgene deal. Maybe just kind of give us your perspective kind of you're -- what pushes and pulls you're hearing from investors. And I have a lot -- quite a bit of follow-up.
Okay. Awesome. So good afternoon, everyone. It's nice to be here. Thanks for inviting us, Geoff. So we're very excited about
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
